Published in Pharma Investments, Ventures and Law Weekly, December 10th, 2006
The fully human IgG1,k antibody, called R1507, which is in Phase I clinical development, was selected from a large panel of antibodies and was found to be very good at binding to its target, the Insulin-like Growth factor-1 Receptor (IGF-1R). R1507 was shown to block binding of IGF-1 and IGF-2, and to potently inhibit IGF-1R signaling. In addition, R1507 was found to effectively stop tumor cell growth in different animal models.
The IGF-1R molecule has been shown to be important in tumor growth and protecting tumor cells from being killed....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.